{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T22:33:22Z","timestamp":1787610802533,"version":"build-2736575974"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T00:00:00Z","timestamp":1536019200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"DOI":"10.3389\/fphar.2018.00953","type":"journal-article","created":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T04:54:10Z","timestamp":1536036850000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":12,"title":["Behavioral Effects of a Potential Novel TAAR1 Antagonist"],"prefix":"10.3389","volume":"9","author":[{"given":"Vincent M.","family":"Lam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catharine A.","family":"Mielnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Baimel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Beerepoot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Espinoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Sukhanov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Horsfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raul R.","family":"Gainetdinov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie L.","family":"Borgland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy J.","family":"Ramsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Salahpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2018,9,4]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S0306-4522(00)00014-2","article-title":"Immunocytochemical localization of the sigma1 receptor in the adult rat central nervous system.","volume":"97","author":"Alonso","year":"2000","journal-title":"Neuroscience"},{"key":"B2","doi-asserted-by":"publisher","first-page":"14057","DOI":"10.1523\/JNEUROSCI.1312-15.2015","article-title":"Modulation by trace amine-associated receptor 1 of experimental parkinsonism, L-DOPA Responsivity, and glutamatergic neurotransmission.","volume":"35","author":"Alvarsson","year":"2015","journal-title":"J. Neurosci."},{"key":"B3","doi-asserted-by":"crossref","first-page":"11017","DOI":"10.1523\/JNEUROSCI.19-24-11017.1999","article-title":"Role of adenosine A2 receptors in brain stimulation reward under baseline conditions and during cocaine withdrawal in rats.","volume":"19","author":"Baldo","year":"1999","journal-title":"J. Neurosci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"22053","DOI":"10.1074\/jbc.M116.749119","article-title":"Pharmacological chaperones of the dopamine transporter rescue dopamine transporter deficiency syndrome mutations in heterologous cells.","volume":"291","author":"Beerepoot","year":"2016","journal-title":"J. Biol. Chem."},{"key":"B5","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nature11691","article-title":"Automated design of ligands to polypharmacological profiles.","volume":"492","author":"Besnard","year":"2012","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","first-page":"20081","DOI":"10.1073\/pnas.0906522106","article-title":"The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system.","volume":"106","author":"Bradaia","year":"2009","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2014.00047","article-title":"The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue.","volume":"5","author":"Brisch","year":"2014","journal-title":"Front. Psychiatry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0028-3908(89)90037-3","article-title":"Relationship between rotational behaviour induced by apomorphine and caffeine in rats with unilateral lesion of the nigrostriatal pathway.","volume":"28","author":"Casas","year":"1989","journal-title":"Neuropharmacology"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.1073\/pnas.98.4.1970","article-title":"The role of the D(2) dopamine receptor (D(2)R) in A(2A) adenosine receptor (A(2A)R)-mediated behavioral and cellular responses as revealed by A(2A) and D(2) receptor knockout mice.","volume":"98","author":"Chen","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.1021\/ci700257y","article-title":"Computation of octanol-water partition coefficients by guiding an additive model with knowledge.","volume":"47","author":"Cheng","year":"2007","journal-title":"J. Chem. Inf. Model."},{"key":"B11","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1111\/cbdd.12367","article-title":"Further insights into the pharmacology of the human trace amine-associated receptors: discovery of novel ligands for TAAR1 by a virtual screening approach.","volume":"84","author":"Cichero","year":"2014","journal-title":"Chem. Biol. Drug Des."},{"key":"B12","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1016\/S0014-2999(96)00665-6","article-title":"Adenosine A2A receptors modulate the binding characteristics of dopamine D2 receptors in stably cotransfected fibroblast cells.","volume":"316","author":"Dasgupta","year":"1996","journal-title":"Eur. J. Pharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.phrs.2016.08.022","article-title":"The hallucinogen D-lysergic diethylamide (LSD) decreases dopamine firing activity through 5-HT1A, D2 and TAAR1 receptors.","volume":"113","author":"De Gregorio","year":"2016","journal-title":"Pharmacol. Res."},{"key":"B14","doi-asserted-by":"publisher","first-page":"16928","DOI":"10.1523\/JNEUROSCI.2502-11.2011","article-title":"Genetic deletion of trace amine 1 receptors reveals their role in auto-inhibiting the actions of ecstasy (MDMA).","volume":"31","author":"Di Cara","year":"2011","journal-title":"J. Neurosci."},{"key":"B15","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/S0306-4522(98)00655-1","article-title":"Selective blockade of serotonin-2C\/2B receptors enhances mesolimbic and mesostriatal dopaminergic function: a combined in vivo electrophysiological and microdialysis study.","volume":"91","author":"Di Giovanni","year":"1999","journal-title":"Neuroscience"},{"key":"B16","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1016\/S0091-3057(01)00705-5","article-title":"Role of serotonin2C receptors in the control of brain dopaminergic function.","volume":"71","author":"Di Matteo","year":"2002","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S0028-3908(99)00047-7","article-title":"SB 242 084, a selective serotonin(2C) receptor antagonist, increases dopaminergic transmission in the mesolimbic system.","volume":"38","author":"Di Matteo","year":"1999","journal-title":"Neuropharmacology"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/stke.2002.120.pl2","article-title":"Infrared-guided laser stimulation of neurons in brain slices.","volume":"2002","author":"Dodt","year":"2002","journal-title":"Sci. STKE"},{"key":"B19","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/sita.200500073","article-title":"Polyethylenimine, a cost-effective transfection reagent.","volume":"6","author":"Ehrhardt","year":"2006","journal-title":"Signal Transduct."},{"key":"B20","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1016\/j.neuropharm.2015.02.010","article-title":"Postsynaptic D2 dopamine receptor supersensitivity in the striatum of mice lacking TAAR1.","volume":"93","author":"Espinoza","year":"2015","journal-title":"Neuropharmacology"},{"key":"B21","doi-asserted-by":"publisher","first-page":"416","DOI":"10.1124\/mol.111.073304","article-title":"Functional Interaction between trace amine-associated receptor 1 and dopamine D2 receptor.","volume":"80","author":"Espinoza","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/S0166-2236(97)01096-5","article-title":"Adenosine-dopamine receptor-receptor interactions as an integrative mechanism in the basal ganglia.","volume":"20","author":"Ferr\u00e9","year":"1997","journal-title":"Trends Neurosci."},{"key":"B23","doi-asserted-by":"publisher","first-page":"7238","DOI":"10.1073\/pnas.88.16.7238","article-title":"Stimulation of high-affinity adenosine A2 receptors decreases the affinity of dopamine D2 receptors in rat striatal membranes.","volume":"88","author":"Ferre","year":"1991","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B24","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.brainres.2006.01.038","article-title":"Involvement of adenosine A2A and dopamine receptors in the locomotor and sensitizing effects of cocaine.","volume":"1077","author":"Filip","year":"2006","journal-title":"Brain Res."},{"key":"B25","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s00213-006-0453-9","article-title":"The effects of the 5-HT2C receptor antagonist SB242084 on locomotor activity induced by selective, or mixed, indirect serotonergic and dopaminergic agonists.","volume":"187","author":"Fletcher","year":"2006","journal-title":"Psychopharmacology"},{"key":"B26","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0031-6997(24)01396-6","article-title":"Actions of caffeine in the brain with special reference to factors that contribute to its widespread use.","volume":"51","author":"Fredholm","year":"1999","journal-title":"Pharmacol. Rev."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1124\/pr.110.003285","article-title":"International union of basic and clinical pharmacology. lXXXI. nomenclature and classification of adenosine receptors\u2013an update.","volume":"63","author":"Fredholm","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"B28","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1021\/acsmedchemlett.5b00449","article-title":"Discovery and characterization of 2-aminooxazolines as highly potent, selective, and orally active TAAR1 agonists.","volume":"7","author":"Galley","year":"2016","journal-title":"ACS Med. Chem. Lett."},{"key":"B29","doi-asserted-by":"publisher","first-page":"5244","DOI":"10.1016\/j.bmcl.2012.06.060","article-title":"Optimisation of imidazole compounds as selective TAAR1 agonists: discovery of RO5073012.","volume":"22","author":"Galley","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B30","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1111\/j.1527-3458.1998.tb00065.x","article-title":"E-5842: a new potent and preferential sigma ligand. preclinical pharmacological profile.","volume":"4","author":"Guitart","year":"1998","journal-title":"CNS Drug Rev."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1016\/j.euroneuro.2015.08.011","article-title":"Trace amine-associated receptor 1 activation silences GSK3 \u03b2 signaling of TAAR1 and D2R heteromers.","volume":"25","author":"Harmeier","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.2174\/157015905774322516","article-title":"The sigma receptor: evolution of the concept in neuropsychopharmacology.","volume":"3","author":"Hayashi","year":"2005","journal-title":"Curr. Neuropharmacol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"11250","DOI":"10.1074\/jbc.M116.774075","article-title":"The sigma-1 receptor modulates dopamine transporter conformation and cocaine binding and may thereby potentiate cocaine self-administration in rats.","volume":"292","author":"Hong","year":"2017","journal-title":"J. Biol. Chem."},{"key":"B34","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1016\/S0006-291X(03)00991-4","article-title":"Oligomerization of adenosine A2A and dopamine D2 receptors in living cells.","volume":"306","author":"Kamiya","year":"2003","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"B35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S0091-3057(01)00486-5","article-title":"Adenosine agonists CGS 21680 and NECA inhibit the initiation of cocaine self-administration.","volume":"68","author":"Knapp","year":"2001","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B36","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1111\/tra.12073","article-title":"A novel assay for measurement of membrane-protein surface expression using a \u03b2-lactamase.","volume":"14","author":"Lam","year":"2013","journal-title":"Traffic"},{"key":"B37","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.ejphar.2015.06.026","article-title":"In-vivo pharmacology of trace-amine associated receptor 1.","volume":"763","author":"Lam","year":"","journal-title":"Eur. J. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"2216","DOI":"10.1039\/C5MD00400D","article-title":"Discovery of trace amine-associated receptor 1 ligands by molecular docking screening against a homology model.","volume":"6","author":"Lam","year":"","journal-title":"Med. Chem. Commun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/j.neuropharm.2014.02.007","article-title":"Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors.","volume":"81","author":"Leo","year":"2014","journal-title":"Neuropharmacology"},{"key":"B40","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1124\/jpet.114.216671","article-title":"Relationship between cerebral sigma-1 receptor occupancy and attenuation of cocaine\u2019s motor stimulatory effects in mice by PD144418.","volume":"351","author":"Lever","year":"2014","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B41","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1124\/jpet.107.132647","article-title":"Trace amine-associated receptor 1 modulates dopaminergic activity.","volume":"324","author":"Lindemann","year":"2008","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B42","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/S0014-2999(01)00968-2","article-title":"Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting \u03c31 receptors produce anti-cocaine effects in mice.","volume":"419","author":"Matsumoto","year":"2001","journal-title":"Eur. J. Pharmacol."},{"key":"B43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/0014-2999(91)90355-T","article-title":"Selective \u03c3 ligands block stimulant effects of cocaine.","volume":"201","author":"Menkel","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"B44","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/S0028-3908(98)00078-1","article-title":"Serotonin (5-HT)(2C) receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo.","volume":"37","author":"Millan","year":"1998","journal-title":"Neuropharmacology"},{"key":"B45","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1124\/jpet.105.084459","article-title":"Primate trace amine receptor 1 modulation by the dopamine transporter.","volume":"313","author":"Miller","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"B46","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/s00213-005-2259-6","article-title":"Susceptibility to conditioned place preference induced by addictive drugs in mice of the C57BL\/6 and DBA\/2 inbred strains.","volume":"181","author":"Orsini","year":"2005","journal-title":"Psychopharmacology (Berl)."},{"key":"B47","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1602\/neurorx.2.4.541","article-title":"Medicinal chemical properties of successful central nervous system drugs.","volume":"2","author":"Pajouhesh","year":"2005","journal-title":"NeuroRx"},{"key":"B48","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/0028-3908(93)90057-A","article-title":"Neuropharmacological profile of a novel and selective ligand of the sigma site: SR 31742A.","volume":"32","author":"Poncelet","year":"1993","journal-title":"Neuropharmacology"},{"key":"B49","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/mp.2012.57","article-title":"A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight.","volume":"18","author":"Revel","year":"2013","journal-title":"Mol. Psychiatry"},{"key":"B50","doi-asserted-by":"publisher","first-page":"8485","DOI":"10.1073\/pnas.1103029108","article-title":"TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity.","volume":"108","author":"Revel","year":"2011","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"B51","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.biopsych.2012.05.014","article-title":"Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics.","volume":"72","author":"Revel","year":"2012","journal-title":"Biol. Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/S0893-133X(97)00033-X","article-title":"Adenosine A2A agonists: a potential new type of atypical antipsychotic.","volume":"17","author":"Rimondini","year":"1997","journal-title":"Neuropsychopharmacology"},{"key":"B53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.pbb.2010.11.016","article-title":"SA 4503 attenuates cocaine-induced hyperactivity and enhances methamphetamine substitution for a cocaine discriminative stimulus.","volume":"97","author":"Rodvelt","year":"","journal-title":"Pharmacol. Biochem. Behav."},{"key":"B54","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.drugalcdep.2010.12.018","article-title":"The sigma receptor agonist SA4503 both attenuates and enhances the effects of methamphetamine.","volume":"116","author":"Rodvelt","year":"","journal-title":"Drug Alcohol Depend."},{"key":"B55","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1016\/0014-2999(93)90059-Q","article-title":"The \u03c3 receptor ligand 1,3-di-(2-tolyl) guanidine in animal models of schizophrenia.","volume":"233","author":"R\u00fcckert","year":"1993","journal-title":"Eur. J. Pharmacol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/j.pneurobio.2007.05.001","article-title":"Adenosine A2A receptors and basal ganglia physiology.","volume":"83","author":"Schiffmann","year":"2007","journal-title":"Prog. Neurobiol."},{"key":"B57","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1007\/s002130051146","article-title":"Actions of adenosine A(2A) receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP.","volume":"147","author":"Shiozaki","year":"1999","journal-title":"Psychopharmacology"},{"key":"B58","first-page":"626","article-title":"Effect of BD 1047, a sigma1 receptor antagonist, in the animal models predictive of antipsychotic activity.","volume":"58","author":"Skuza","year":"2006","journal-title":"Pharmacol. Rep."},{"key":"B59","doi-asserted-by":"publisher","first-page":"8195","DOI":"10.1523\/JNEUROSCI.1301-06.2006","article-title":"RNA interference screen reveals an essential role of Nedd4-2 in dopamine transporter ubiquitination and endocytosis.","volume":"26","author":"Sorkina","year":"2006","journal-title":"J. Neurosci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/j.bmcl.2010.12.075","article-title":"Selective antagonists of mouse trace amine-associated receptor 1 (mTAAR1): discovery of EPPTB (RO5212773).","volume":"21","author":"Stalder","year":"2011","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"B61","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/syn.20281","article-title":"[123I]TPCNE\u2014A novel SPET tracer for the sigma-1 receptor: first human studies and in vivo haloperidol challenge.","volume":"60","author":"Stone","year":"2006","journal-title":"Synapse"},{"key":"B62","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/0006-8993(95)01223-0","article-title":"Effects of selective adenosine A1 and A2a agonists on amphetamine-induced locomotion and c-Fos in striatum and nucleus accumbens.","volume":"707","author":"Turgeon","year":"1996","journal-title":"Brain Res."},{"key":"B63","doi-asserted-by":"publisher","first-page":"D400","DOI":"10.1093\/nar\/gkr1132","article-title":"PubChem\u2019s bioassay database.","volume":"40","author":"Wang","year":"2012","journal-title":"Nucleic Acids Res."},{"key":"B64","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/j.1601-183X.2006.00292.x","article-title":"The Trace Amine 1 receptor knockout mouse: an animal model with relevance to schizophrenia.","volume":"6","author":"Wolinsky","year":"2007","journal-title":"Genes Brain Behav."},{"key":"B65","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/0306-4522(95)00171-E","article-title":"Reduction of dopamine D2 receptor transduction by activation of adenosine A2a receptors in stablyA2a\/D2 (long-form) receptor co-transfected mouse fibroblast cell lines: studies on intracellular calcium levels.","volume":"68","author":"Yang","year":"1995","journal-title":"Neuroscience"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00953\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,6]],"date-time":"2025-07-06T20:58:38Z","timestamp":1751835518000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fphar.2018.00953\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,4]]},"references-count":65,"alternative-id":["10.3389\/fphar.2018.00953"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2018.00953","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,4]]},"article-number":"953"}}